Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Timothy Cragin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5730-3019; OpenAlex author ID A5100373179. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 4 papers

Papers 9

  1. Proteomics profiling of research models for studying pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41597-025-04522-x↗
  2. A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery. Co-author DOI 10.1093/oncolo/oyaf162↗
  3. Translational studies on pancreatic cancer and gastric cancer: a methodology in PhD thesis. Co-author DOI 10.3389/fphar.2025.1604017↗
  4. Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer. Co-author DOI 10.3390/proteomes13020020↗
  5. Nerves on tr[ac]k to support pancreatic cancer metabolism. First author DOI 10.1038/s41422-020-00462-w↗
  6. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Last author DOI 10.1136/gutjnl-2019-319912↗
  7. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-20-0285↗
  8. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cance… Co-author DOI 10.1155/2019/6402925↗
  9. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Last author DOI 10.1016/j.ccell.2017.11.007↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mathilde Resell · 3 shared papers, 2025 · strength 0.68
  2. Chun‐Mei Zhao · 3 shared papers, 2025 · strength 0.68
  3. Ruth Aroon White · 3 shared papers, 2021–2025 · strength 0.61
  4. Manoj Amrutkar · 2 shared papers, 2025 · strength 0.41
  5. Surinder K. Batra · 2 shared papers, 2025 · strength 0.41
  6. Caroline Sophie Verbeke · 2 shared papers, 2025 · strength 0.41
  7. Anil K. Rustgi · 2 shared papers, 2025 · strength 0.41
  8. Gulam Abbas Manji · 2 shared papers, 2020–2025 · strength 0.32
  9. África González‐Fernández · 1 shared paper, 2025 · strength 0.27
  10. Ryota Takahashi · 3 shared papers, 2018–2021 · strength 0.26
  11. Kenneth P. Olive · 3 shared papers, 2018–2021 · strength 0.26
  12. Kazuki N. Sugahara · 1 shared paper, 2025 · strength 0.22
  13. Susan Elaine Bates · 1 shared paper, 2025 · strength 0.22
  14. Michael D. Kluger · 1 shared paper, 2025 · strength 0.22
  15. Beth Schrope · 1 shared paper, 2025 · strength 0.22
  16. John A. Chabot · 1 shared paper, 2025 · strength 0.22
  17. Paul E. Oberstein · 1 shared paper, 2025 · strength 0.22
  18. Tamas A. Gonda · 2 shared papers, 2020–2021 · strength 0.21
  19. Alina Cornelia Iuga · 2 shared papers, 2018–2021 · strength 0.16
  20. Takayuki Tanaka · 2 shared papers, 2018–2021 · strength 0.16
  21. Marina Macchini · 2 shared papers, 2018–2021 · strength 0.16
  22. Bernhard Willibald Renz · 2 shared papers, 2018–2021 · strength 0.16
  23. Christoph Benedikt Westphalen · 2 shared papers, 2018–2021 · strength 0.16
  24. Masaki Sunagawa · 1 shared paper, 2021 · strength 0.11
  25. Jeanine M. Genkinger · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.